SCHEMBL642867

SCHEMBL642867

CCOP(=O)(OCC)C(F)(F)c1cccc(N)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.47
MAPK1 P28482 1/20 0.47
PGK1 P00558 3/20 0.41
PGK2 P07205 3/20 0.41
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PTPN5 P54829 3/20 0.37
PTPN1 P18031 1/20 0.36
CCNT1 O60563 2/20 0.36
CDK9 P50750 2/20 0.36
PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL642678 0.85 TSHR (0.45) TSHRMAPK1PGK1PGK2TP53
SCHEMBL14303549 0.83 PTPN5 (0.50) TSHRPGK1PGK2CYP3A4ALDH1A1
SCHEMBL5795784 0.82 PTPN1 (0.48) TSHRMAPK1ALDH1A1NPSR1LMNA
SCHEMBL10128394 0.81 TSHR (0.44) TSHRMAPK1PGK1PGK2TP53
SCHEMBL2036856 0.81 PGK1 (0.38) TSHRPGK1PGK2TP53CYP3A4
Hydrochloric Acid SCHEMBL5215511 0.80 MAOB (0.37) TSHRPGK1PGK2TP53CYP3A4
SCHEMBL642080 0.78 NPSR1 (0.46) PGK1PGK2ALDH1A1NPSR1LMNA
SCHEMBL643448 0.77 PTPRC (0.50) TSHRMAPK1CYP3A4ALDH1A1NPSR1
SCHEMBL14303548 0.73 TSHR (0.39) TSHRMAPK1TP53CYP3A4ALDH1A1
SCHEMBL643902 0.73 ALDH1A1 (0.40) TSHRMAPK1ALDH1A1NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2057173-B1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2014-02-26 EP disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-8119617-B2 aSMase inhibitors NOVARTIS AG (CH) 2012-02-21 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
US-20100022482-A1 aSMase inhibitors NOVARTIS AG (CH) 2010-01-28 US disclosed
EP-2057173-A1 AMIDES AS SPHINGOMYELINE INHIBITORS Novartis AG (CH) 2009-05-13 EP disclosed
WO-2008022771-A1 AMIDES AS SPHINGOMYELINE INHIBITORS NOVARTIS AG (CH) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022482-A1 aSMase inhibitors SMPD1, SMPD3, SMPD2 TSHR 2541/4885MAPK1 3198/4885PGK1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.